ME/CFS

Myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) are overlapping names for a chronic, disabling, multisystem illness; current clinical practice commonly uses the combined term ME/CFS . ME is not synonymous with uncomplicated chronic fatigue: fatigue is a nonspecific symptom, whereas ME/CFS requires a characteristic pattern of exertion-triggered symptom worsening, impaired function, and additional sleep, cognitive, or autonomic symptoms. ^[1]

The clinical discriminator is post-exertional malaise (PEM), also called post-exertional symptom exacerbation. PEM is a delayed, disproportionate worsening of the patient’s baseline symptoms after physical, cognitive, emotional, or orthostatic stress; recovery may be prolonged. A patient who feels tired after exertion but returns to baseline with ordinary rest does not, by that feature alone, have ME/CFS. The National Academy of Medicine describes PEM as an exacerbation of some or all ME/CFS symptoms after physical or cognitive stressors that were previously tolerated, whereas the 2021 NICE guideline emphasizes delayed onset, disproportionate severity, and prolonged recovery. ^[1]

The core illness pattern combines four clinical domains. First, function falls substantially below the patient’s pre-illness level because ordinary physical or cognitive demands provoke symptom exacerbation. Second, sleep is unrefreshing or non-restorative: patients may sleep for a long time yet wake without the expected restoration of energy or alertness. Third, cognitive impairment may present as slowed processing, impaired attention, reduced working memory, or difficulty finding words. Fourth, orthostatic intolerance , symptoms provoked or worsened by upright posture, may cause light-headedness, palpitations, weakness, nausea, impaired concentration, or a need to lie down. ^[5][7][8]

No validated diagnostic biomarker establishes or excludes ME/CFS. Candidate abnormalities in exercise physiology, immunology, metabolism, autonomic function, and neuroimaging remain investigational, and some proposed tests have limited ability to distinguish ME/CFS from other fatiguing illnesses. Diagnosis therefore remains clinical: identify the characteristic symptom pattern, document the effect on function and recovery after exertion, assess duration, and investigate alternative or coexisting disorders. ^[3][14]

How the principal case definitions differ

The 2015 National Academy of Medicine (NAM; formerly the Institute of Medicine) criteria, often used in CDC clinical materials, require all three core features, substantial reduction or impairment in the ability to engage in usual activities, PEM, and unrefreshing sleep, plus at least one of cognitive impairment or orthostatic intolerance. In adults, symptoms must persist for at least 6 months; in children and adolescents, the usual threshold is 3 months. The criteria are designed for clinical recognition and place PEM at the center of the diagnosis. ^[1]

The 2021 NICE guideline uses a shorter diagnostic timeline. Consider ME/CFS when all four cardinal symptoms are present: debilitating fatigue that is worsened by activity, PEM, unrefreshing sleep, and cognitive difficulty. Symptoms should have been present for at least 3 months before diagnosis, should substantially reduce functional ability, and should not be better explained by another condition. NICE does not require cognitive impairment and orthostatic intolerance as interchangeable alternatives; cognitive difficulty is one of its four core symptoms, while orthostatic symptoms are assessed as part of the broader clinical picture. ^[1]

The 2003 Canadian Consensus Criteria (CCC) are more expansive and phenotypically restrictive. They require clinically significant fatigue, PEM, sleep dysfunction, and pain, together with at least two neurological or cognitive manifestations and symptoms from at least two of the autonomic, neuroendocrine, and immune categories. The illness must be present for at least 6 months in adults, with a shorter duration generally accepted in children. Because CCC requires multisystem manifestations beyond fatigue and PEM, it is often used to assemble more homogeneous research cohorts, although it is less streamlined for primary-care diagnosis. ^[1]

Across the definitions, the shared requirements are persistent functional impairment, PEM, and disturbed restorative sleep, together with exclusion of a better alternative explanation. The important differences are the minimum duration, 3 months in NICE versus 6 months in NAM and CCC, the symptom breadth demanded by CCC, and the way cognitive and orthostatic symptoms are operationalized. A patient may therefore meet one definition but not another without the underlying clinical presentation being fabricated or trivial; the clinician should record which definition was applied and describe the actual symptoms and functional consequences in plain language. ^[1][3]

Pearl: Do not diagnose ME/CFS from chronic fatigue alone. Ask what happens after exertion, when the worsening begins, how long recovery takes, whether sleep restores function, and whether cognition or upright posture reliably worsens symptoms. ^[1]

ME/CFS often begins after an acute infectious illness, but the initiating event is not a sufficient explanation for the chronic disease. Reported antecedents include infectious mononucleosis caused by Epstein-Barr virus (EBV), COVID-19 , influenza-like illnesses, and other viral syndromes; earlier observations particularly implicated EBV, enteroviruses, and other infections.^[3] A prospective study of students followed from before infectious mononucleosis supports a temporal association rather than a universal outcome: illness severity at 6 months helped distinguish those with persistent ME/CFS at 7 years, while many participants recovered or had only lingering symptoms.^[25]

Acute infection may therefore be best regarded as a precipitating event in a susceptible host. The susceptibility model remains provisional. A 2026 combinatorial genetic analysis identified reproducible combinations of single-nucleotide variants associated with ME, mapping to genes involved in neurological regulation, inflammation, cellular stress responses, and calcium signaling; these findings suggest polygenic predisposition, not a clinically validated genetic test or a deterministic inherited cause.^[23] Host factors may alter immune recovery, autonomic adaptation, vascular regulation, or metabolic reserve, but no genetic or laboratory profile currently establishes who will develop ME/CFS after infection.

The same caution applies to noninfectious precipitants. Major physiologic stress, including surgery, trauma, prolonged sleep disruption, severe metabolic strain, or another systemic illness, may precede onset or worsen an established illness, but the evidence is less specific than for postinfectious onset. Proposed models describe a first stressor that creates biological vulnerability and a second stressor, such as exertion, that exposes impaired recovery; this remains a mechanistic framework rather than a diagnostic rule.^[12] Ask about the temporal sequence of infection, injury, surgery, medication changes, sleep loss, and exertional escalation, but do not infer causation from chronology alone.

Proposed biology is best understood as a network model, not as a set of established diagnostic tests. Candidate mechanisms include immune dysregulation, autonomic nervous-system disturbance, impaired cellular energy metabolism, vascular and endothelial dysfunction, abnormal skeletal-muscle and cardiopulmonary responses, and altered sensory processing. Reviews describe these domains as incompletely understood, and their abnormalities are neither sufficiently reproducible nor specific to confirm or exclude ME/CFS.^[1] Studies comparing post-COVID condition and ME/CFS have found overlapping autonomic, small-fiber, cognitive, and vascular findings, but the investigators explicitly caution that overlap does not establish identical disease trajectories or convergence.^[26]

Immune dysregulation is biologically plausible because an acute infection can leave persistent immune signaling, altered cellular trafficking, or maladaptive immune-metabolic coupling after the pathogen has been cleared. However, peripheral inflammatory markers are inconsistent: in one controlled cross-sectional study of long-COVID fatigue, conventional inflammatory and cellular-stress biomarkers did not differ significantly from recovered controls.^[31] This limits the clinical value of single cytokine measurements and argues against treating a nonspecific laboratory abnormality as evidence of an ongoing infection.

The metabolic hypothesis proposes that impaired adaptation to stress, rather than a simple lack of stored energy, could explain delayed recovery. Mitochondrial redox imbalance, altered oxidative phosphorylation, impaired calcium handling, and abnormal skeletal-muscle signaling could reduce the capacity to meet a sudden demand; exertion might then reveal a defect that is not apparent at rest.^[1][12] These mechanisms remain hypotheses. Resting or post-exertional metabolomic abnormalities are research findings, not validated bedside tests, and no mitochondrial supplement or metabolic drug has established disease-modifying efficacy on the basis of the ME/CFS diagnosis alone.

Autonomic and vascular hypotheses provide a parallel explanation for stress intolerance. Disturbed sympathetic-parasympathetic regulation, impaired venous return, endothelial dysfunction, or abnormal microvascular control could compromise orthostatic and exertional adaptation. A prospective retinal-vessel study found persistent endothelial and microvascular abnormalities in post-COVID condition, with the most pronounced changes in participants fulfilling ME/CFS criteria, but this was an observational association and not a diagnostic standard.^[28] Use orthostatic assessment and targeted cardiovascular testing when clinically indicated; do not infer a specific vascular lesion from symptoms alone.

Skeletal muscle and cardiopulmonary responses may be altered through impaired excitation-contraction coupling, redox stress, oxygen-utilization abnormalities, or delayed recovery after exertion. Results from repeated cardiopulmonary exercise testing are heterogeneous: one recent study found no significant day-to-day change in peak oxygen consumption or ventilatory threshold and concluded that its two-day protocol should not define PEM or disability.^[15] Cardiopulmonary exercise testing therefore remains a specialized research or differential-diagnostic tool, not a routine confirmatory test for ME/CFS.

Sensory-processing hypotheses extend beyond peripheral sensory organs. In an event-related potential study, people with ME/CFS reported more sensory problems and had reduced P300 responses, while an earlier sensory-gating measure did not differ from controls; the authors interpreted this as possible involvement of higher-order control processes.^[29] Such findings may help generate mechanistic questions, but they do not justify routine neurophysiologic testing or a sensory-directed treatment pathway.

Persistent infection has not been demonstrated as a universal cause. Evidence for viral persistence, latent or abortive reactivation, and residual pathogen products remains pathogen-specific, method-dependent, and incomplete; even the herpesvirus literature includes repeated failure to demonstrate active replication.^[3] Consequently, a positive antibody result, a suspected viral reactivation, or the timing of illness cannot establish that an infectious agent is maintaining ME/CFS.

Do not prescribe routine antimicrobials, antivirals, or immunomodulators solely because a patient meets ME/CFS criteria. The rationale is clinical as well as evidentiary: proposed immune, metabolic, autonomic, vascular, and sensory mechanisms have not produced a validated treatment target, while available studies do not establish a universal active infection.^[1][3] Treat a documented infection or a separately established immune-mediated disease according to its own evidence-based indications, and keep experimental immunomodulatory therapy within appropriately governed clinical research.

ME/CFS is common enough to be encountered in ordinary primary care, but its measured frequency depends heavily on what investigators count as a case. Estimates span approximately 0.4-0.6% in general populations, up to 0.75% in pediatric populations, and 1.3% of U.S. adults reporting a current clinician diagnosis in the 2021-2022 National Health Interview Survey (NHIS). ^[33][4] These figures are not interchangeable: some studies use a clinician-recorded diagnosis, some use self-report, some recruit from specialist services, and others apply symptom questionnaires that may identify chronic fatigue or CFS-like illness rather than clinically adjudicated ME/CFS. ^[4][34] Differences in the applied case definition also alter the numerator; definitions differ in duration requirements and symptom breadth, and registry cohorts may include people meeting Fukuda, Canadian Consensus, or International Consensus criteria rather than one uniform standard. ^[4][17]

Ascertainment is therefore part of the epidemiology, not a technical footnote. A population survey can capture people who never reach specialist care, but self-reported diagnosis may include historical or disputed diagnoses and cannot distinguish current illness from recovery, diagnostic replacement, or diagnostic error. ^[4] Conversely, administrative and specialist datasets preferentially capture patients who have access to clinicians able to recognize and code the illness. In Norway and the United Kingdom, recorded incidence was lower in more deprived postcodes or households, a pattern interpreted as evidence that access to diagnosis affects apparent incidence. ^[33] The NHIS authors likewise describe ME/CFS as often undiagnosed, misdiagnosed, or attributed to other physical or mental disorders; a recent specialist-service study states that the majority of people with ME/CFS remain undiagnosed. ^[4][39] The observed prevalence is consequently a lower-bound estimate in many settings, although symptom-screening studies can overestimate it by including people who have not undergone adequate clinical evaluation.

The age distribution is not confined to older adults. Health-record studies and a large European survey suggest two broad onset concentrations: one in adolescence and another in early-to-middle adulthood, with modeled means near 16 and 37 years. ^[33] Age at diagnosis must not be mistaken for age at onset, because diagnostic delay is substantial; in the cited European data, mean delay ranged from 5 years in the United Kingdom and 6 years in Norway to as long as 12 years in other European countries. ^[33] In U.S. survey data, however, adults aged 60-69 were the most common age group among those reporting a current or past diagnosis. ^[4] That apparent contrast is clinically useful: older adults may be diagnosed more often because illness has persisted into later life or because contact with health services creates more opportunities for recognition, whereas onset studies may reveal a genuine adolescent and young-adult burden obscured by delay.

Children and adolescents do develop ME/CFS, and pediatric illness should not be dismissed as school avoidance, deconditioning, or ordinary adolescent tiredness. A 2026 survey of 8,840 secondary-school students in Shaanxi reported a 2.059% CFS screening detection rate, but this was a questionnaire-based school study rather than a population estimate based on specialist clinical assessment. ^[34] Its value is therefore chiefly epidemiologic signal: young people with persistent activity-related illness may be present in schools without entering medical datasets. The European onset analysis found the early peak centered in adolescence, and early-onset respondents more often reported infectious triggers, particularly infectious mononucleosis, than late-onset respondents. ^[33] These findings support active recognition across pediatric and adult services without implying that every adolescent with fatigue has ME/CFS.

Women are diagnosed more often than men. European and international summaries describe approximately four female diagnoses for every male diagnosis, while the NHIS found that women comprised 68.0% of adults with current ME/CFS compared with 51.2% of adults who reported never having the illness. ^[33][4] This is an association, not evidence that female sex causes ME/CFS. It may reflect biological susceptibility, differences in exposure, symptom expression, help-seeking, diagnostic expectations, or a combination of these factors; current epidemiologic data cannot assign the relative contribution of each. Sex-related ascertainment also matters because a male or gender-diverse patient with a compatible illness may be overlooked when clinicians unconsciously treat ME/CFS as predominantly a disorder of women.

Postinfectious illness is a major route into ME/CFS but not a prerequisite. Prospective studies after infectious mononucleosis have reported ME/CFS in approximately 10% of participants at 12 months, while infection was the most frequently reported precipitant in European survey respondents. ^[33] SARS-CoV-2 infection has added a large population of people with prolonged postinfectious illness; Long COVID and ME/CFS overlap clinically, but they are not synonymous diagnoses. ^[24][23] In a tertiary pediatric Long COVID registry, 24% of participants met criteria for ME/CFS, a figure that cannot be extrapolated to all children with SARS-CoV-2 infection because the cohort was already enriched for severe post-COVID illness. ^[11] A reported infectious trigger should therefore increase clinical attention to ME/CFS rather than substitute for assessment of the characteristic illness pattern.

Familial aggregation is plausible but does not follow a simple Mendelian pattern. Genetic studies identify many associated variants across immune, neurologic, cellular-stress, and calcium-signaling pathways, and the available evidence supports polygenic susceptibility rather than a deterministic “ME/CFS gene.” ^[23] A family history may therefore indicate shared susceptibility or shared exposures, but it neither confirms the diagnosis nor predicts that an unaffected relative will develop it. The same caution applies to reported associations with depression, autoimmune disease, or other comorbidity: cross-sectional and observational associations do not establish that those conditions cause ME/CFS or that they precede it in every patient. ^[4][36]

Socioeconomic disadvantage is visible both in prevalence estimates and in consequences. In the NHIS, 20.7% of adults with current ME/CFS reported living below the federal poverty line, compared with 9.8% of adults who had never reported ME/CFS; current illness was also associated with markedly greater work limitation and disability. ^[4] Poverty may increase exposure to illness, reduce the ability to rest or modify demands, and make specialist assessment unaffordable, while disabling illness can itself cause loss of employment and income. The direction is therefore bidirectional, and demographic disparity must not be misread as causation.

Race and ethnicity require the same discipline. The NHIS found disproportionate representation of American Indian/Alaska Native, White, and non-Hispanic adults among those reporting current ME/CFS, with Asian, Hispanic, and other-race adults underrepresented relative to respondents without ME/CFS. ^[4] A New Zealand benefit-based cohort similarly found disproportionate representation of European people and underrepresentation of Māori, Pacific, and Asian groups, but that cohort represented only people receiving a health- or disability-related benefit and therefore cannot estimate ethnic prevalence in the whole population. ^[35] These patterns may reflect differences in exposure, recognition, referral, language, trust, insurance, diagnostic coding, or eligibility for support; they do not demonstrate racial or ethnic biological causation.

Rural residence was not associated with a statistically significant difference between current and past ME/CFS in adjusted U.S. analyses, but that finding does not prove equitable access to specialist assessment. ^[4] Rurality, transportation, fluctuating disability, limited clinician experience, financial constraints, and the need for language-concordant communication can all affect whether a patient reaches a clinician familiar with ME/CFS; the available surveillance data capture these barriers incompletely. Specialist referral cohorts should therefore be read as service-use populations, not as the disease population. The central primary-care implication is epidemiologic fairness: absence from a specialist register, employment, school attendance, older age, male sex, minority racial or ethnic identity, poverty, rural residence, or limited English proficiency should not be treated as evidence against ME/CFS.

Post-exertional malaise (PEM) is the clinical feature that gives the ME/CFS phenotype its distinctive shape. A patient may worsen after physical effort, but also after sustained concentration, conversation, emotional stress, prolonged upright posture, heat, noise, or visually demanding activity. The worsening may begin immediately, several hours later, or over the next few days; its severity is disproportionate to the activity, and recovery may take days or weeks rather than resolving after an ordinary night's sleep. ^[12][45] PEM can amplify existing symptoms or introduce new ones, including cognitive slowing, pain, dizziness, sensory hypersensitivity, gastrointestinal upset, and flu-like malaise. ^[12] Repeated episodes may produce a relapsing or fluctuating course, with incomplete return to the patient's previous baseline after some exacerbations. ^[45]

Ask what the patient can do reliably, not what was possible on the best day. The relevant exposure is the person's usual activity threshold: a shower, meal preparation, a short conversation, reading, sitting upright, or a brief trip outside may be sufficient to provoke PEM in severe disease. Patients with greater impairment may deteriorate after challenges far below the workload used in formal exercise testing. ^[45] Record the activity, the latency to worsening, the symptoms that changed, the duration of recovery, and whether function returned to baseline. This history is more clinically informative than a generic statement that exercise is difficult.

PEM differs from ordinary exertional fatigue and from deconditioning . Deconditioning lowers capacity because inactivity reduces cardiovascular and muscular reserve; exertion may then feel difficult during the activity, but recovery generally follows a predictable pattern. In ME/CFS, the defining problem is an abnormal post-exertional trajectory: symptoms may be delayed, multisystem, and prolonged, with a level of perceived effort that exceeds the measured task. In a two-day cardiopulmonary exercise study, patients with ME/CFS had greater perceived exertion and lower maximal heart rate than sedentary controls, but peak oxygen consumption and ventilatory-threshold measures did not decline significantly on day 2; this illustrates why exercise-test performance alone neither confirms nor excludes PEM. ^[15]

The phenotype is usually variable rather than uniform. Sleep, cognition, autonomic symptoms, pain, sensory tolerance, and gastrointestinal symptoms may change independently, and the same activity may be tolerated one day but provoke PEM another day. Postinfectious onset is common, and the illness may fluctuate after the initial infection rather than follow a steadily progressive course. ^[24][45] Emotional or cognitive activity is not a lesser trigger: planning, problem-solving, social interaction, and distress can consume the patient's available functional reserve just as physical exertion can. ^[12]

Sleep is commonly prolonged yet non-restorative. Patients may spend more time in bed without a corresponding increase in total sleep time and may have poor or unstable sleep efficiency from night to night. ^[8] Ask about difficulty falling asleep, repeated or early awakening, excessive sleep duration, daytime sleepiness, and whether sleep produces any recognizable improvement. Some patients report insomnia with a “wired but tired” state; others have hypersomnia, irregular timing, or sleep-wake reversal in which alertness shifts toward the night. These descriptions should prompt assessment for coexisting sleep disorders, medication effects, mood disorder, circadian disruption, and other medical causes rather than being attributed automatically to ME/CFS.

Cognitive impairment is usually experienced as “brain fog”: slowed processing, impaired attention, word-finding difficulty, reduced working memory, poor multitasking, and loss of executive efficiency. ^[7] The patient may read the same paragraph repeatedly, lose the thread of a conversation, struggle to retrieve familiar words, or become unable to make routine decisions. Cognitive symptoms often worsen during PEM and may be provoked by mental effort even when the patient is physically still. ^[12] A normal brief office interaction does not exclude meaningful disability; ask how long the patient can read, use a screen, converse, drive, study, or manage finances before symptoms escalate.

Orthostatic intolerance is a symptom complex triggered or worsened by sitting or standing. Patients may describe light-headedness, dizziness, palpitations, tremulousness, weakness, nausea, impaired concentration, visual dimming, or near-fainting; symptoms may improve when they lie down. ^[5] Heat, bathing, prolonged standing, and postprandial periods can expose the limitation. Ask how long the patient can stand, whether symptoms occur during a shower or while waiting in line, whether the heart feels fast or forceful, and whether there has been actual syncope. Orthostatic symptoms may coexist with low blood volume, vascular or respiratory abnormalities, or autonomic dysregulation, and static blood-volume measurements do not reliably account for all orthostatic abnormalities. ^[47]

Autonomic symptoms extend beyond posture. Patients may report temperature dysregulation, abnormal sweating or chills, heat intolerance, cold intolerance, flushing, altered bowel function, urinary symptoms, and palpitations. These complaints often cluster with dizziness and cognitive clouding rather than appearing as isolated cardiovascular symptoms. ^[5][32] Pain may be diffuse or regional, musculoskeletal, neuropathic, pressure-like, burning, or worsened by activity; headache may accompany cognitive or sensory symptoms. Flu-like sensations, sore throat, malaise, chills, tender glands, and a feeling of being acutely unwell without a new infection, may wax and wane with PEM. ^[1][9][37]

Sensory hypersensitivity can involve light, sound, touch, smell, motion, or visual complexity. A busy shop, bright screen, loud conversation, or ordinary clothing may become intolerable, particularly during PEM. Sensory hypersensitivity commonly clusters with headache, sleep disturbance, and cognitive symptoms, although proposed neurobiological explanations remain associative rather than proven causal mechanisms. ^[32][7] Gastrointestinal symptoms range from nausea, abdominal pain, bloating, altered stool frequency, reflux, food intolerance, and irritable-bowel-type complaints. They are clinically relevant because greater gastrointestinal burden has been associated with more fatigue, cognitive difficulty, pain, sleep disturbance, flu-like symptoms, and sensory complaints. ^[9]

The clinical signal is the combination of these domains and their temporal behavior: a delayed, disproportionate, prolonged response to activity; unrefreshing and unstable sleep; cognitive inefficiency; orthostatic and sensory intolerance; and fluctuating pain, flu-like, and gastrointestinal symptoms. No single symptom, normal examination between episodes, or isolated exercise result captures the phenotype. ^[1][8][15]

Begin with the patient’s own account of change from their pre-illness baseline. Ask what they could reliably do before illness, work or school, exercise, household tasks, social activity, driving, and self-care, and what they can reliably do now. Document the date and tempo of onset, any preceding infection, surgery, trauma, pregnancy, major stressor, medication change, or other illness, while treating chronology as a clue rather than proof of causation. A sudden onset is common in specialty cohorts, but gradual onset also occurs ^[50].

History

Characterize the activity reduction in concrete terms: hours upright, walking distance, time spent outside the home, tolerance of showering, meal preparation, conversation, reading, screen use, and attendance at work or school. Ask separately about a best day, a usual day, and a bad day; the reliable usual capacity is more useful than the patient’s maximum performance. Establish the patient’s current activity envelope, the amount and type of physical, cognitive, emotional, sensory, or upright activity that can be completed without provoking a delayed worsening, and record which activities lie beyond it. The illness is heterogeneous, so functional impairment may be severe in one domain and relatively limited in another ^[49].

Elicit post-exertional malaise with an event-based history rather than a generic fatigue score. Ask: “What activity preceded the worsening?” “How long after it did symptoms begin?” “Which symptoms changed or appeared?” “How long until you returned to your usual baseline?” and “Has recovery ever remained incomplete?” Include physical effort, prolonged upright posture, cognitive work, emotional stress, heat, noise, light, travel, and clinical encounters. Even basic activities can exceed the patient’s tolerance in severe illness, and worsening may include pain, cognitive dysfunction, orthostatic symptoms, sensory intolerance, gastrointestinal symptoms, or flu-like malaise ^[49]. Record the patient’s baseline and post-exertional function in the same terms so that future changes are interpretable.

Ask about sleep duration, sleep timing, sleep latency, awakenings, early waking, naps, sleep-wake reversal, snoring, witnessed apneas, restless legs, and whether sleep refreshes the patient. Review sedating or activating medicines, caffeine, alcohol, cannabis, other substances, circadian disruption, mood symptoms, and prior sleep-disorder evaluation; do not assume that unrefreshing sleep is caused by ME/CFS alone. Specialty-clinic assessments have found sleep disturbance and unrefreshing sleep across patients, with substantial heterogeneity in symptom measures ^[50].

Assess cognition in activities that matter to the patient: sustained attention, reading, word finding, working memory, multitasking, following conversation, using a computer or telephone, and managing finances or medicines. Ask whether cognitive effort provokes delayed worsening and whether communication is easier by writing, texting, an assistive device, or a support person. Normal conversational performance during a short visit does not establish normal cognitive capacity across a full day; functional assessment should include the patient’s report and, when appropriate, collateral history ^[49].

Ask about orthostatic symptoms in relation to posture and relief with recumbency: light-headedness, palpitations, tremulousness, weakness, nausea, visual dimming, presyncope, syncope, breathlessness, and cognitive clouding. Record triggers such as standing, showering, heat, meals, or prolonged sitting. Ask about temperature regulation, sweating, bowel and bladder symptoms, and exertional or positional chest discomfort. Review pain by location, quality, severity, frequency, duration, triggers, and effect on sleep and function; include headache, myalgia, arthralgia, allodynia, jaw pain, and sensory hypersensitivity. Pain is associated with reduced physical functioning and quality of life in ME/CFS cohorts ^[58].

Review every prescribed medicine, over-the-counter product, supplement, contraceptive, hormone preparation, and intermittent drug, including dose, timing, indication, benefit, adverse effects, and recent changes. Ask specifically about stimulants, sedatives, antihistamines, analgesics, opioids, antidepressants, antihypertensives, and drugs that may worsen sleep, cognition, nausea, or orthostatic symptoms. Record nicotine, alcohol, cannabis, recreational drugs, caffeine, and withdrawal or use patterns. Ask directly about depression, anxiety, trauma, hopelessness, self-harm, and suicidal thoughts, while keeping somatic symptoms and functional loss analytically separate from psychiatric symptoms; psychological distress may coexist with ME/CFS but should not be used to explain the illness without adequate assessment ^[49].

Assess nutrition through appetite, early satiety, nausea, dysphagia, abdominal pain, diarrhea or constipation, food intolerance, food access, ability to shop and prepare meals, fluid intake, and the energy required to eat. Ask about weight change, menstrual regularity, pregnancy possibility, lactation, contraception, menopausal symptoms, and whether symptoms vary with the menstrual cycle. Pregnancy testing and medication review should be guided by reproductive possibility and clinical context. Obtain family history of ME/CFS-like illness, autoimmune disease, neurologic disease, dysautonomia, sleep disorders, migraine, and relevant inherited conditions without treating familial aggregation as diagnostic. Ask about housing, caregiving, finances, transportation, health-literacy or language needs, safety, isolation, occupational exposures, and access to food and disability support; social and practical barriers can materially worsen morbidity ^[49].

Examination

Adapt the examination to the patient’s activity envelope. Arrange a quiet, low-stimulation environment; explain each step; permit pauses; minimize unnecessary transfers, prolonged conversation, bright light, noise, touch, and waiting. Ask whether the patient wants a support person present and whether a caregiver should provide collateral history. For a homebound or bedbound patient, use a home visit or telehealth-supported assessment when appropriate. A routine office examination should not become an unplanned exertional challenge, because overexertion can worsen symptoms ^[49].

Measure temperature, heart rate, blood pressure, respiratory rate, oxygen saturation when clinically indicated, weight when safe, and pain. Observe work of breathing, perfusion, hydration, posture, speech, alertness, affect, psychomotor speed, and ability to sustain interaction. Perform supine cardiovascular and respiratory examination, then neurologic examination of mental status, cranial nerves as indicated, tone, power, reflexes, sensation, coordination, gait, and balance; examine joints, muscles, skin, and range of motion according to symptoms. Look for focal neurologic deficits, synovitis, objective weakness, cardiorespiratory abnormalities, fever, dehydration, edema, pressure injury, falls-related injury, and nutritional compromise. Interpret a normal brief examination cautiously: it does not measure the patient’s capacity over hours or the delayed response to exertion ^[50].

Measure orthostatic heart rate and blood pressure only when clinically safe and tolerated. Record the starting position, duration of each position, symptoms, pulse, blood pressure, and reason for stopping; do not insist on prolonged standing or provoke syncope. If the patient cannot stand safely, document that limitation and use a tolerated alternative such as supine-to-sitting assessment, collateral history, or home measurements rather than treating inability to complete the maneuver as a negative result. Do not require a maximal exercise test to establish the functional baseline. Cardiopulmonary exercise testing remains a physiologic research or selected clinical tool, not a substitute for the history of delayed symptom exacerbation; exercise testing alone does not define ME/CFS ^[50].

Functional baseline and documentation

Document basic activities of daily living, bathing, dressing, toileting, transferring, continence, feeding, and communication, and instrumental activities such as cooking, shopping, cleaning, laundry, transportation, employment or schooling, finances, and medication management. Record the assistance, equipment, time, and recovery required for each task. Add mobility status: independent walking, cane, walker, wheelchair, bedbound status, falls, and tolerance of sitting or standing. Record work or school hours, absences, accommodations, cognitive workload, and the effect of commuting or attendance. Include communication modality, sensory accommodations, caregiver availability, and whether the patient can attend clinic without substantial post-exertional worsening.

A written baseline should include usual daily upright time, tolerable activity duration, symptom variability, frequency and duration of exacerbations, typical recovery time, and the patient’s current activity envelope. Repeat the same measures at follow-up rather than relying on a global impression. Patient-reported measures can complement the interview; the PROMIS Physical Function Short Form 12a showed satisfactory reliability and validity in adults with ME/CFS, but no questionnaire replaces clinical judgment and a task-specific history ^[51]. Do not prescribe increased activity from a baseline measure alone. Use the record to prevent advice or testing that exceeds the patient’s demonstrated tolerance.

Diagnosis of ME/CFS is a positive clinical determination based on a characteristic pattern of illness, not a label assigned after every conceivable disease has been excluded. No single biomarker provides a definitive diagnosis, and symptom patterns overlap with other disorders; the clinician must therefore document the defining features, assess plausible alternative explanations, and continue ordinary care for coexisting disease. ^[39]

A stepwise diagnostic approach

1. Establish a substantial change from baseline. Ask what the patient could reliably do before illness and what they can do now on a usual day, rather than on an unusually good day. Record effects on self-care, domestic tasks, mobility, work or school, communication, and social participation. The reduction must be clinically meaningful and persistent or relapsing; fatigue without demonstrable functional loss is insufficient.

2. Characterize post-exertional malaise (PEM). Ask about physical, cognitive, emotional, sensory, and upright activities separately. Identify the activity that triggered worsening, the latency to deterioration, which symptoms changed or appeared, how long recovery took, and whether the patient returned to baseline. PEM may follow an activity that the patient considers modest, and a delayed, prolonged, multisystem exacerbation distinguishes it from ordinary tiredness or simple deconditioning. Use the patient’s reliable activity threshold, not the maximum they achieved once.

3. Confirm the associated symptom domains. Determine whether sleep is unrefreshing despite adequate opportunity for sleep, and ask specifically about slowed thinking, impaired attention, word-finding, working memory, or difficulty multitasking. Assess orthostatic intolerance by asking whether standing or remaining upright causes dizziness, palpitations, tremulousness, weakness, nausea, visual dimming, cognitive clouding, presyncope, or syncope, and whether lying down helps. A normal brief conversation or examination does not establish normal sustained cognitive or physical capacity.

4. Verify duration and trajectory. Apply the duration threshold of the chosen framework rather than combining thresholds informally. NICE permits diagnosis after 3 months of symptoms; the 2015 NAM/CDC framework generally uses at least 6 months in adults and at least 3 months in children and adolescents; the Canadian Consensus Criteria (CCC) traditionally use at least 6 months in adults, with a shorter interval accepted in young people. Across frameworks, the illness must be persistent or recurrent and unexplained by a better alternative. ^[68]

5. Evaluate alternative explanations without demanding exhaustive exclusion. Perform a history, examination, medication and substance review, and targeted investigations guided by the presentation and red flags. Look for a condition that better explains the whole syndrome, while recognizing that an abnormality found during evaluation may explain only part of it. ME/CFS can coexist with fibromyalgia , migraine , postural orthostatic tachycardia syndrome , sleep apnea , depression , autoimmune disease, endocrine disease, or other illness; treating such a condition does not invalidate ME/CFS if the defining symptom pattern persists.

6. Apply one case definition transparently. State the framework used, the date symptoms began, the duration at assessment, the functional consequences, the PEM pattern, and which required or alternative criteria are present. Do not diagnose from fatigue severity, an abnormal autonomic test, a patient’s illness trigger, or a proposed biomarker alone. Current diagnostic frameworks rely predominantly on reported symptoms, and standardized symptom assessment is needed because reliable biomarkers are absent. ^[68][70]

A prospective symptom and activity record can convert an apparently vague history into a reproducible clinical pattern. Ask the patient, or a caregiver when appropriate, to record daily activity by domain, symptom severity, trigger and latency of PEM, recovery time, sleep quality, cognitive performance, upright tolerance, and assistance required. Review the record at follow-up rather than asking the patient to increase activity to test the diagnosis; deliberately provoking PEM is neither necessary nor ethically justified. Repeated records are also useful when symptoms fluctuate, the initial history is incomplete, or the clinician is distinguishing a stable activity limitation from delayed post-exertional deterioration.

In children and young people, obtain collateral information from parents or carers and document attendance, reduced school hours, missed lessons, concentration, homework tolerance, sports and play, self-care, and recovery after ordinary school days. Do not interpret school absence, irritability, or reduced participation in isolation: link the functional change to PEM, unrefreshing sleep, cognitive difficulty, and the other required domains. Use age-appropriate language and allow breaks during assessment. A child need not describe symptoms in adult terms for the pattern to be clinically evident.

When the pattern is suggestive but duration or criterion coverage is incomplete, communicate uncertainty explicitly: for example, “probable ME/CFS, PEM and substantial functional reduction documented; duration currently 8 weeks, reassess after 3 months.” Give the patient a working plan that protects the current activity envelope, treats identified comorbidities, and specifies when reassessment will occur. Reassess if the illness evolves, because symptoms fluctuate and overlapping conditions can obscure the phenotype. A provisional diagnosis is not diagnostic failure; it is safer than either premature certainty or indefinite investigation.

The frameworks are not interchangeable diagnostic tests. NICE emphasizes the combination of debilitating fatigue, PEM, unrefreshing sleep, cognitive difficulty, and substantial functional reduction; NAM/CDC makes cognitive impairment and orthostatic intolerance alternatives within its core symptom set; CCC requires a broader multisystem phenotype. The 2003 Canadian criteria deliberately expanded the definition to include neurologic and immunologic manifestations, whereas later frameworks refined the diagnostic approach. ^[68] A patient may therefore satisfy one framework but not another. Record the definition used and avoid presenting disagreement between definitions as proof that the illness is absent.

Pearl: Diagnose ME/CFS from the pattern, substantial functional decline, PEM, unrefreshing sleep, and the required cognitive, autonomic, or broader multisystem features, then keep the diagnosis under review as duration, comorbidities, and the patient’s functional trajectory become clearer.

Fatigue, delayed symptom worsening, poor sleep, cognitive slowing, and orthostatic symptoms are not specific to ME/CFS. Overlapping presentations create a risk of both missed treatable disease and premature attribution to ME/CFS; no single laboratory biomarker currently provides a definitive diagnosis.^[39][42] Use the history and examination to decide which alternatives are plausible, then order a small initial panel rather than a broad untargeted screen.

Organize the differential by presentation and urgency

First identify conditions that require same-day assessment. Send the patient for urgent evaluation when fatigue accompanies chest pain, new dyspnea at rest, hypoxemia, sustained or exertional syncope, new focal neurologic deficit, delirium, rapidly progressive weakness, severe dehydration, gastrointestinal bleeding, major hemorrhage, suicidal intent, mania with impaired judgment, or unexplained fever with hemodynamic instability. Investigate new focal, abrupt, severe, or steadily progressive symptoms on their own merits; do not explain them by ME/CFS or by post-exertional malaise .

Next separate systemic and sleep-related mimics from disorders that chiefly produce orthostatic or neurocognitive symptoms. Ask whether the patient has weight loss, fever, night sweats, bleeding, polyuria or polydipsia, heat or cold intolerance, hyperpigmentation, inflammatory morning stiffness, rash, swollen joints, focal weakness, sensory loss, witnessed apneas, restless legs, medication changes, intoxication, withdrawal, restrictive eating, or pregnancy risk. A delayed, multisystem worsening after activity supports ME/CFS, but it does not protect the patient from a second diagnosis. Longitudinal follow-up matters because new medical and psychiatric diagnoses may emerge after an ME/CFS label; one 16-year follow-up of previously diagnosed women reported substantial later somatic or psychiatric disease burden, although the small, highly selected cohort limits generalization.^[18]

Orthostatic symptoms deserve a parallel assessment rather than automatic attribution to POTS . Document supine and standing heart rate and blood pressure when safe, together with symptoms, posture, duration, and reason for stopping. In one ME/CFS cohort, POTS was defined as a heart-rate increase of at least 30 beats/min or an absolute heart rate of at least 120 beats/min during a 10-minute lean test; static blood-volume categories did not predict orthostatic abnormalities.^[47] Confirm persistent or unexplained syncope, marked tachycardia, arrhythmia, exertional symptoms, or abnormal examination with electrocardiography , ambulatory monitoring, echocardiography, or specialist autonomic/cardiovascular assessment as indicated. Do not provoke symptoms with maximal exercise testing: a recent two-day cardiopulmonary exercise testing|CPET study found no significant day-to-day change in peak oxygen consumption or ventilatory threshold and concluded that the protocol should not define PEM or disability.^[15]

Pragmatic primary-care investigations

For most adults with persistent unexplained fatigue, begin with CBC, ferritin, electrolytes, renal function, liver function, calcium, glucose or HbA1c, TSH, ESR or CRP, and urinalysis. Add a pregnancy test when pregnancy is possible. This panel searches for common hematologic, endocrine, metabolic, renal, hepatic, inflammatory, and urinary explanations without turning nonspecific abnormalities into a diagnosis.

Order B12 or folate for macrocytosis, anemia, neuropathy, glossitis, malnutrition, malabsorption, or a restrictive diet. Order vitamin D when deficiency risk, bone pain, or muscle weakness makes the result clinically actionable. Order CK for objective proximal weakness, myalgia with weakness, dark urine, statin exposure, or suspected inflammatory or metabolic myopathy; isolated fatigue without weakness is a poor reason for indiscriminate CK testing. Order HIV, hepatitis, EBV, or other serology only when exposure, clinical syndrome, or examination supports it. Positive serology may document previous exposure rather than active infection; do not infer persistent infection or prescribe antimicrobial therapy from seropositivity alone.

Use an ECG for palpitations, syncope, exertional symptoms, persistent tachycardia, chest discomfort, or relevant medication exposure. Obtain chest imaging, pulmonary function testing, echocardiography, ambulatory rhythm monitoring, brain or spine imaging, or nerve studies only when symptoms, examination, or the initial panel supplies a specific indication. Arrange sleep testing for prominent snoring, witnessed apneas, gasping, unexplained hypersomnolence, resistant hypertension, or persistent non-restorative sleep that cannot be explained clinically. Sleep abnormalities in ME/CFS can include poor efficiency and marked night-to-night variability, so a normal single night does not settle the broader sleep assessment.^[82]

Interpret every result in clinical context. Mild isolated ESR, CRP, ferritin, transaminase, glucose, TSH, or leukocyte abnormalities may reflect transient illness, obesity, medication exposure, menstrual status, laboratory variation, or another incidental process. Review pretest probability before ordering panels: the more tests performed in a low-risk patient, the more likely an incidental abnormality becomes. Repeat an unexpected, borderline, or internally inconsistent result after an appropriate interval, provided the patient is clinically stable; repeat sooner or escalate when the abnormality is severe, progressive, or accompanied by red flags. Do not use normal routine tests to invalidate substantial functional impairment, and do not use an abnormal nonspecific result as proof of ME/CFS.

When the initial evaluation is unrevealing, reassess rather than endlessly expand testing. Review the activity and symptom record, medication and substance changes, menstrual and nutritional history, sleep pattern, orthostatic measurements, mood trajectory, and objective functional change. A negative test excludes only the disorder it adequately assesses; it does not exclude ME/CFS, and it does not eliminate the possibility of a later-emerging comorbidity. Observation with planned reassessment is active clinical care when the patient is stable, because fluctuating illness and evolving disease may not be captured at one visit.^[85]

Pearl: Investigate the symptom that does not fit: progressive focal weakness, objective inflammation, persistent fever, major weight loss, exertional cardiopulmonary symptoms, or orthostatic syncope warrants a new diagnostic pathway even when the patient also has a convincing ME/CFS phenotype.

Severity in ME/CFS is a clinical description of lost function and symptom burden, not a synonym for fatigue intensity. Record the patient’s pre-illness baseline, reliable usual capacity, worst recent capacity, assistance required, and the consequences of activity across physical, cognitive, upright, sensory, and social domains. A patient who can complete a task once but develops delayed, multisystem worsening for days afterward has less usable capacity than a brief examination may suggest. Health-related quality of life is substantially impaired in people with ME/CFS, and symptom clusters differ in severity and frequency across patients. ^[17]

NICE functional categories

Use the NICE categories as practical descriptors rather than rigid stages. Mild illness permits self-care and some domestic, educational, occupational, or social activity, but only with reduced hours, frequent rests, and careful control of activity. Mobility is usually preserved, although prolonged standing, walking, travel, or cognitive work may provoke symptoms. Communication is generally possible, while concentration, noise, light, or visual demand may reduce the patient’s usable capacity.

Moderate illness substantially restricts work, education, domestic activity, and social participation. The patient may remain independently mobile indoors and manage personal care, but tasks are slower, divided into small steps, or followed by recovery periods. The patient is often largely housebound because travel, upright time, sensory exposure, or sustained conversation exceeds the available activity envelope. Orthostatic symptoms and cognitive effort may limit function as much as walking.

Severe illness leaves the patient mostly housebound and often confined to bed or a chair for much of the day. Personal care and meals may require assistance; transfers and short periods of walking may be possible but costly. Communication may be brief or intermittent because speech and conversation are cognitively and physically demanding. Light, sound, touch, movement, screens, or other sensory input may need to be reduced, and assessment may require a quiet home or telehealth approach.

Very severe illness leaves the patient bedbound and dependent for basic care. Movement may be limited to essential repositioning or transfers, often requiring assistance or equipment. Speech may be absent, limited to short phrases, or replaced by nonverbal communication. The patient may tolerate only brief, low-stimulation contact and may require a darkened, quiet environment with care delivered at home or at the bedside. Do not infer preserved function from a single successful interaction; the energy cost may be apparent only later.

These categories describe functional impact, not a permanent disease stage. Severity can change across days or weeks because the activity envelope is affected by sleep disruption, orthostatic stress, infection, pain, cognitive or emotional demand, sensory exposure, and incomplete recovery from an earlier exacerbation. The category may therefore differ between domains: a patient may walk independently yet be unable to sustain conversation, tolerate light, or remain upright long enough to prepare food. Longitudinal registry data likewise identify clinically meaningful differences in symptom severity, frequency, and health-related quality of life rather than a single uniform phenotype. ^[17]

Measuring function and symptom burden

Begin with an activity and symptom diary for at least several representative days, extending the record when the patient’s response is delayed. For each activity, record its type and duration, posture, cognitive or sensory demand, symptom change, onset of worsening, recovery time, and whether the patient returned to baseline. Include essential activities such as showering, dressing, meal preparation, speaking, reading, screen use, travel, and medical visits. A diary is most useful when it captures the patient’s reliable usual threshold rather than an exceptional best-day performance.

Record orthostatic symptoms separately. Document posture, time upright, dizziness, palpitations, tremor, weakness, nausea, visual dimming, presyncope, syncope, cognitive clouding, heart rate, blood pressure when safely obtained, and the reason for stopping. A symptom record remains informative when standing measurements are unsafe or intolerable; inability to stand is a functional finding, not a negative orthostatic test.

The DSQ is a structured patient-reported questionnaire that captures autonomic and neuroendocrine-immune symptoms, cognitive dysfunction, sleep disturbance, and post-exertional malaise. ^[87] Use the DSQ or DSQ-Short Form to standardize symptom characterization and follow change, but interpret scores alongside the history of delayed worsening and observed function. PROMIS instruments can quantify domains such as physical function, fatigue, cognition, and social participation; select short forms that the patient can complete without provoking cognitive or sensory overload. EQ-5D summarizes health status across mobility, self-care, usual activities, pain or discomfort, and anxiety or depression, while the Chalder Fatigue Scale measures fatigue-related severity rather than the full functional phenotype. A small pilot pacing study used Chalder fatigue and SF-36 physical-function scores as exploratory outcomes, which supports their use for measurement but does not establish them as staging instruments. ^[88]

Repeat the same measure under comparable conditions and specify the recall period. A score change is interpretable only when the patient’s activity, illness state, assistance, and mode of completion are also documented. When cognition, speech, or sensory tolerance limits self-report, obtain collateral information from a caregiver or school record and label the source. The DSQ has been used with other standardized questionnaires in ME cohorts, but questionnaire scores do not replace clinical judgment. ^[87]

No single scale stages ME/CFS. A functional questionnaire may miss delayed post-exertional worsening; a fatigue scale may underrepresent orthostatic or sensory disability; and a quality-of-life measure may be influenced by pain, mood, housing, caregiving, and access to support. Maximal cardiopulmonary exercise testing is not a substitute for longitudinal functional assessment: in one two-day study, peak oxygen consumption, ventilatory-threshold oxygen consumption, and ventilatory efficiency did not significantly change between days in patients with ME/CFS, and the investigators concluded that the protocol did not define PEM or disability. ^[15] The patient’s post-exertional trajectory, what triggered worsening, when it began, which symptoms changed, how long recovery took, and whether baseline returned, therefore carries more clinical information than any single performance measurement.

Pearl: Classify severity by what the patient can sustain safely and repeatedly, then verify the classification against delayed post-exertional consequences rather than the task completed during the consultation.

Energy management is the central intervention for preventing avoidable deterioration in ME/CFS . The aim is not to increase activity to a predetermined target, but to keep total demand within the patient’s current activity envelope: the amount of physical, cognitive, emotional, social, sensory, and upright activity that can be repeated without delayed symptom exacerbation. Establish the envelope from reliable usual function, not a best day, and review the latency, symptom pattern, and recovery after activity. NICE advises people with ME/CFS to remain within their energy limit, avoid pushing through symptoms, and balance activity with regular rest; this recommendation is individualized rather than quota-based. ^[90] Pacing is intended to stabilize function and reduce the likelihood of PEM , although the supporting intervention literature remains limited and heterogeneous. ^[89]

Begin with baseline stabilization. Ask the patient to identify essential activities, activities that can be delayed or delegated, and the early signs that demand is approaching the limit. For several representative days, record activity type and duration, posture, cognitive or sensory load, symptoms during and after the task, the delay before worsening, and time to recovery. Treat the lowest consistently reproducible capacity as the working baseline. Do not set the baseline from a single good day, and do not use a diary to encourage progressive increases. The patient and clinician should agree on priorities, acceptable trade-offs, and a plan for a bad day; family, carers, school, and employers may participate with the patient’s consent. Collaborative baseline-setting and an agreed setback plan were associated with better rehabilitation experiences in a qualitative survey, whereas pressure to exceed a sustainable baseline was associated with negative experiences. ^[102]

Translate pacing into practical conservation. Fragment tasks into short episodes separated by recovery; alternate higher-demand and lower-demand activities; sit or lie down for tasks that do not require standing; simplify meals, washing, communication, and household work; use delivery, prepared food, voice-to-text, written instructions, one-task scheduling, and delegation when these reduce demand. Plan rest before predictable exertion rather than waiting for a crash. Rest may involve lying down, reducing conversation, darkness or low sensory input, and avoiding cognitively demanding media; its duration and frequency must be individualized because prolonged daytime sleep can also disrupt nocturnal sleep. NICE advises that rest form part of the daily routine and be reviewed as needs change. ^[90]

Assess every activity domain separately. A patient may tolerate a short walk but not a shower, sustained conversation, bright light, computer work, or prolonged upright posture. Emotional effort, social interaction, sensory stimulation, and decision-making consume the same limited reserve as physical movement for pacing purposes. Use mobility aids, shower seating, transfer equipment, wheelchairs, or other adaptations when they reduce upright demand and preserve essential participation; an aid is an energy-conservation tool, not evidence of treatment failure. NICE recommends aids and adaptations when they help maintain independence and quality of life. ^[90]

Heart-rate or symptom monitoring can help some patients recognize an approach to their limit, particularly when orthostatic symptoms are prominent, but it is an aid to judgment rather than a universal prescription. Do not impose a fixed heart-rate ceiling, exercise zone, step count, or daily quota when that target conflicts with symptoms or provokes delayed worsening. Symptom and recovery trajectories are more clinically useful than a single activity score, and monitoring itself should not become an additional cognitive burden. ^[89]

Pacing is not graded exercise therapy (GET). GET is a fixed or quota-based programme that requires progressive increases in physical activity or exercise, often on the assumption that deconditioning is the principal cause of disability. Pacing instead adjusts activity downward or upward according to the patient’s current envelope and delayed response. It is also distinct from “push-crash” cycling, in which a patient spends a good day’s reserve and then remains inactive during a prolonged crash. NICE advises against GET and against any generic programme of fixed incremental activity or exercise for ME/CFS; NICE also advises that any physical activity programme offered in selected cases must remain within the person’s energy limit and be delivered by a physiotherapist in an ME/CFS specialist team. ^[90] A deconditioning-based rehabilitation model is unsafe when it interprets PEM as ordinary exercise intolerance and responds by escalating the load; ordinary strengthening or conditioning should be considered only for a specific indication, at a dose the patient can tolerate without delayed deterioration, and with an explicit stop-and-recovery plan. Evidence supporting pacing is less robust than its clinical use, whereas the evidence reviewed by NICE for GET was low or very low quality and included qualitative evidence of potential harm. ^[90]

Shared decision-making is essential because the acceptable balance between activity, independence, symptom burden, and participation differs across patients and changes over time. Refer to occupational therapists and physical therapists who understand ME/CFS, PEM, orthostatic intolerance, sensory sensitivity, and adaptive equipment. Their task is to reduce the cost of necessary activity and improve access, not to enforce exercise progression. NICE recommends individualized multidisciplinary care, and qualitative work emphasizes patient collaboration, early support, clinician training, and flexible delivery. ^[90][94]

During PEM, stop attempts to maintain the previous schedule. Reduce activity to the level required for hydration, nutrition, toileting, medication, communication, and safety; lie down or recline for orthostatic symptoms; lower sensory and cognitive input; and postpone, delegate, or cancel nonessential tasks. Resume other activities only after symptoms have stabilized and the patient feels able, beginning at the newly tolerated level rather than automatically returning to the former baseline. Severe, sustained, or atypical worsening warrants clinical review for a new complication or comorbidity rather than attribution to ME/CFS alone. NICE advises patients during relapse to prioritize essential daily activities, adjust energy management to current limits, and resume other activities only after stabilization. ^[90]

Increase activity only after sustained stability, with the patient’s agreement and without a predetermined increment. Change one demand at a time, make the smallest practicable adjustment, and observe for delayed worsening over the patient’s usual PEM window before retaining the change. If symptoms worsen, return to the last stable level; a reduction is a therapeutic adjustment, not a failure. The endpoint is durable participation within the activity envelope, not normalization of exercise capacity.

Treat symptoms without spending the patient’s limited physiologic reserve. NICE advises individualized management and rejects fixed-increment exercise programmes; the D-A-CH consensus likewise places symptom-directed treatment after protection from post-exertional worsening and recommends adjusting medication dose and timing to the patient’s tolerance ^[90][91]. Start one intervention at a time, use the lowest reasonable dose, review delayed worsening over several days, and stop a treatment that increases sedation, cognitive impairment, orthostatic symptoms, or post-exertional symptom exacerbation.

Sleep

Ask whether the problem is sleep initiation, sleep maintenance, early awakening, hypersomnia, a reversed sleep-wake schedule, or sleep that remains unrefreshing despite adequate opportunity. Do not attribute every sleep complaint to ME/CFS: review caffeine, alcohol, cannabis, nicotine, antihistamines, stimulants, sedatives, analgesics, antidepressants, and withdrawal states, and assess for obstructive sleep apnea when there is snoring, witnessed apnoea, nocturnal gasping, obesity, resistant hypertension, or disproportionate daytime sleepiness. Arrange polysomnography or home sleep-apnea testing when the history warrants it. Evaluate restless legs syndrome when there is an urge to move the legs, unpleasant evening or nocturnal sensations, or relief with movement; check ferritin and investigate iron deficiency before prescribing dopaminergic therapy. Sleep in ME/CFS may be unstable from night to night, so a several-day diary is often more informative than a single-night impression ^[8].

Adapt sleep hygiene to disability rather than prescribing an unrealistic routine. Keep wake time and light exposure as regular as the patient can tolerate; obtain gentle morning or daytime light when possible, reduce bright or stimulating light in the evening, and avoid forcing early rising if it provokes orthostatic symptoms or PEM. Use a quiet, dark, temperature-controlled room, but permit daytime rest when required for symptom stability. Separate the bed from prolonged wakeful activity when feasible, while allowing recumbent alternatives for patients who cannot sit or stand for long. Stable daytime light exposure was associated with better sleep and autonomic symptom profiles in an observational cohort, but causality was not established ^[6].

Consider melatonin when circadian delay or difficulty initiating sleep predominates: melatonin 0.5-3 mg orally 1-2 hours before the desired bedtime for 2-4 weeks is a cautious trial. Reassess for vivid dreams, morning sedation, headache, dizziness, and drug interactions. If insomnia persists, choose a clinician-selected sedating medicine according to the phenotype rather than escalating empirically; examples include doxepin 3-6 mg orally at bedtime or trazodone 25-50 mg orally at bedtime. Avoid routine benzodiazepines and sedating antihistamines because dependence, falls, anticholinergic effects, worsened cognition, and orthostatic hypotension may outweigh benefit. Treat confirmed sleep apnea or iron deficiency directly rather than escalating hypnotics.

Pain and headache

Characterize pain before treating it: distinguish diffuse nociplastic pain, muscle or joint pain without inflammatory findings, neuropathic burning or electric pain, headache, and pain amplified during PEM. Use heat, gentle massage, supported positioning, topical preparations, and brief, recumbent physical strategies that do not provoke delayed worsening. For localized nociceptive pain, try acetaminophen 500-1000 mg orally every 6-8 hours as needed, not exceeding 3,000 mg/day in routine use; reduce the maximum or avoid it in liver disease, heavy alcohol use, or low body weight. If inflammation or acute musculoskeletal pain is plausible, ibuprofen 200-400 mg orally every 6-8 hours with food, for the shortest possible course, may be used; avoid NSAIDs in active gastrointestinal bleeding or ulcer disease, significant kidney disease, decompensated heart failure, uncontrolled hypertension, anticoagulant-associated high bleeding risk, or pregnancy when contraindicated.

For neuropathic or widespread pain, choose one agent and titrate slowly. Amitriptyline 5-10 mg orally at bedtime can be increased by 5-10 mg every 1-2 weeks, usually not beyond 50 mg nightly in this context. Duloxetine 20-30 mg orally each morning can be increased to 60 mg daily after 1-2 weeks if tolerated. Gabapentin 100-300 mg orally at night can be increased every 3-7 days toward 300 mg three times daily; adjust for renal function. Pregabalin 25-75 mg orally at bedtime can be increased to 75 mg twice daily, with renal adjustment. These are symptom treatments, not ME/CFS disease-modifying therapies. Warn about sedation, dizziness, cognitive slowing, falls, edema, weight change, serotonin toxicity with interacting drugs, and withdrawal; use extra caution when orthostatic intolerance is prominent. Avoid chronic opioids when possible because of sedation, constipation, dependence, hyperalgesia, and interference with functional assessment.

Treat headache according to its phenotype. A migraine-like headache may justify early oral acetaminophen or ibuprofen when safe, followed by a migraine-specific agent such as sumatriptan 50 mg orally at onset, repeatable once after 2 hours, with a maximum of 200 mg/day; avoid triptans in established coronary or cerebrovascular disease and do not use acute headache medicines on frequent days because of medication-overuse headache. New, abrupt, progressive, positional, exertional, febrile, focal, or neurologic headache requires independent evaluation rather than attribution to ME/CFS. Refer to neurology or a headache service for diagnostic uncertainty, persistent disability despite treatment, medication overuse, or red flags.

Orthostatic intolerance

First distinguish POTS from orthostatic hypotension , vasovagal syncope, arrhythmia, structural heart disease, dehydration, anemia, medication effect, and seizure. POTS requires orthostatic symptoms with a sustained heart-rate rise of at least 30 beats/min in adults, or at least 40 beats/min in children, without orthostatic hypotension; orthostatic hypotension is defined by a sustained systolic fall of at least 20 mmHg or diastolic fall of at least 10 mmHg within 3 minutes of standing ^[107]. Record supine and standing heart rate, blood pressure, symptoms, and duration when safe. Obtain an ECG for unexplained syncope or marked palpitations, and arrange ambulatory monitoring, echocardiography, or cardiology review when arrhythmia, exertional syncope, abnormal examination, or structural disease is possible. POTS is not a sufficient explanation for every faint; prolonged loss of consciousness, exertional syncope, chest pain, sustained arrhythmia, injury, or focal neurologic features require urgent assessment.

Use conservative measures first. Increase fluids, often toward 2-3 L/day, and salt intake only when hypertension, kidney disease, heart failure, hypernatremia, or another contraindication is absent; the 2026 supervised protocol studied 3 L of fluid and 10 g of salt daily, but adherence was variable and the study was small ^[97]. Use waist-high or abdominal compression, cooling, slow transitions from lying to sitting to standing, leg crossing or calf activation, and seated or recumbent activity. Avoid prolonged standing, hot environments, large alcohol exposures, and unnecessary fasting. A recumbent intervention is preferable to upright conditioning when activity itself provokes PEM; do not prescribe fixed exercise increments.

Reserve medication for persistent, objectively documented or clinically compelling symptoms after review of volume status and causative drugs. Fludrocortisone 0.05-0.1 mg orally each morning may be titrated to 0.2 mg/day with monitoring of supine blood pressure, potassium, edema, and weight. Midodrine 2.5-5 mg orally three times daily during waking hours may be increased to 10 mg three times daily; avoid within 4 hours of bedtime and monitor for supine hypertension, urinary retention, and piloerection. For prominent tachycardia, propranolol 10 mg orally one to three times daily or metoprolol 12.5-25 mg orally once or twice daily may be trialled cautiously; avoid or modify treatment in asthma, bradycardia, hypotension, conduction disease, and hypoglycaemia risk. Ivabradine 2.5-5 mg orally twice daily may be considered by an autonomic or cardiology specialist, with monitoring for bradycardia, atrial fibrillation, visual phenomena, and drug interactions. Evidence for pharmacologic POTS treatment remains limited, and a systematic review found that large randomized trials are lacking ^[107]. Refer to autonomic medicine or cardiology for syncope, diagnostic uncertainty, severe tachycardia, hypotension, failed conservative measures, or need for combination therapy.

Comorbid and fluctuating symptoms

For nausea, early satiety, reflux, constipation, or diarrhoea, review hydration, meal size, medication effects, iron and magnesium supplements, NSAIDs, and alarm features before prescribing. Use small, frequent meals and identify reproducible dietary triggers without imposing restrictive diets that worsen nutrition. Treat constipation with polyethylene glycol 17 g orally daily, titrated to effect; for diarrhoea, loperamide 2 mg orally after the first loose stool, then 2 mg after each subsequent stool, up to 8 mg/day for short-term use, provided fever, blood, inflammatory diarrhoea, and ileus are absent. Refer for weight loss, bleeding, persistent vomiting, nocturnal symptoms, anaemia, progressive dysphagia, or persistent unexplained pain.

Allergy-like symptoms, rhinitis, pruritus, flushing, urticaria, or episodic gastrointestinal symptoms, require confirmation of the clinical syndrome rather than assuming mast-cell disease. Remove a clear trigger when possible; cetirizine 5-10 mg orally daily or loratadine 10 mg orally daily is less sedating than first-generation antihistamines, but even these may worsen fatigue, cognition, or orthostasis in susceptible patients. Refer to allergy/immunology for recurrent angioedema, wheeze, anaphylaxis, multisystem episodes, or suspected drug allergy. Treat recurrent infections, endocrine disease, anaemia, migraine, fibromyalgia, depression, anxiety, sleep disorders, and gastrointestinal disease on their own diagnostic evidence rather than attributing them to ME/CFS.

Review every medication at each visit. Reduce anticholinergic, sedating, hypotensive, and stimulating burden where possible; align dosing with the patient’s most reliable functional period, and taper drugs that can cause withdrawal rather than stopping them abruptly. NICE describes CBT, when used, as supportive rather than curative, and advises against fixed-increment exercise; neither should be presented as treatment for the underlying disease ^[90]. Antivirals, stimulants, intravenous immunoglobulin, rituximab, and other experimental immunologic or metabolic therapies are not routine ME/CFS treatments. EUROMENE states that no causal treatment exists and that care is symptom-oriented ^[106]; use these therapies only for a separately established indication or within appropriate research governance.

Coexisting illness is common in ME/CFS and should be sought actively rather than treated as a competing explanation for every symptom. A second diagnosis may account for a new, focal, progressive, or treatment-responsive feature without invalidating ME/CFS; conversely, an overlapping symptom must not be used to diagnose a comorbidity without its own clinical evidence. The ME/CFS- irritable bowel syndrome association is substantial, but available studies are heterogeneous and establish association rather than causality. ^[111]

Use a problem list that separates ME/CFS, comorbid diseases, symptoms of uncertain attribution, and unresolved red flags. For each important symptom, record its baseline pattern, relation to posture or meals, latency after activity, recovery time, and response to treatment. This prevents fibromyalgia , migraine , POTS , sleep disease, mood disorder, or long COVID from becoming diagnostic substitutes, while preventing ME/CFS from becoming an explanation for anemia, thyroid disease, infection, inflammatory disease, cardiopulmonary disease, pregnancy, or malignancy.

Medication reconciliation is a safety intervention, not clerical work. At every substantial review, reconcile prescriptions, over-the-counter medicines, supplements, hormones, intermittent agents, caffeine, alcohol, cannabis, nicotine, and recreational drugs; identify duplicate ingredients, recent withdrawals, and agents that worsen sedation, cognition, nausea, sleep, blood pressure, or orthostasis. Start one new treatment at a time at the lowest reasonable dose, define the target symptom and review date, and stop or reduce an intervention that causes delayed worsening. A specialist-clinic cohort found that medication use before referral was concentrated in pain- and anxiety-related treatment, while other symptom-directed pharmacotherapy was limited; primary care should therefore neither undertreat documented comorbidity nor offer unsupported disease-modifying regimens. ^[38]

Create a shared, current record containing the applied ME/CFS case definition, reliable usual and worst-day function, activity envelope, PEM latency and recovery, orthostatic findings, allergies, medication trials and adverse effects, investigations, safety plan, communication needs, and the patient’s priorities. Give the patient a concise copy for emergency and specialist visits. Use one agreed medication list and one coordinating clinician; ask consultants to state which symptoms they believe they are treating, what change would count as benefit, what adverse effects require cessation, and how their plan interacts with pacing and other conditions. Continuity and consistent follow-up are particularly valuable because people with ME/CFS report contradictory activity advice and care that does not match physical or cognitive limitations. ^[44]

Adapt access before the appointment rather than asking the patient to tolerate a standard pathway. Offer telehealth, asynchronous history, home or collateral assessment, longer appointments, clustered investigations, quiet and dimly lit rooms, permission to lie down, minimal transfers, scheduled pauses, accessible toilets, written questions, captioning, communication aids, and a support person when desired. Send the agenda and required forms in advance; allow delayed responses and post-visit written instructions because cognitive and sensory load can itself consume the patient’s activity reserve. Flexible digital, hybrid, and modular delivery has been identified as a preferred form of support by people with ME/CFS and their next of kin. ^[44]

Prioritize care by immediate risk, reversible disease, functional importance, and treatment burden. Address chest pain, dyspnoea at rest, sustained syncope, focal neurologic deficit, delirium, rapidly progressive weakness, severe dehydration or bleeding, hemodynamic instability, anaphylaxis, suicidal intent, or impaired-judgment mania urgently. For nonurgent care, agree on one or two goals, protect the current activity envelope, and defer low-yield investigations or simultaneous medication changes. This approach treats coexisting illness without converting every fluctuation into a new test, a new specialist pathway, or an unsafe demand for exertion.

Pearl: Treat ME/CFS and the coexisting condition as two clinical realities: preserve the patient’s sustainable activity envelope while investigating and treating every independent disease on its own evidence.

A crash is an acute, disproportionate worsening of baseline symptoms after physical, cognitive, emotional, upright, sensory, or procedural demand; onset may be immediate or delayed, and recovery may take days to weeks. ^[76] A relapse is a more sustained deterioration in function or symptom burden, often after a trigger, with failure to return to the patient’s recent baseline. ME/CFS has a prolonged, relapsing course, so document the patient’s pre-event baseline rather than assuming that every fluctuation represents disease progression. ^[115]

Common precipitants include infection, surgery or another procedure, exertion beyond the patient’s reliable threshold, sleep disruption, and psychological or cognitive stress. ^{[76] [115]} Ask what happened in the preceding 1-7 days, when worsening began, which symptoms changed or appeared, whether oral intake and toileting remain possible, and whether function has returned to baseline. Treat the event as a potential acute illness when the pattern is new, focal, abrupt, severe, or qualitatively different from prior crashes; do not attribute fever, hypoxaemia, persistent syncope, delirium, bleeding, or rapidly progressive weakness to ME/CFS without assessment. ^[76]

During a crash, reduce demands immediately to essential hydration, nutrition, prescribed medicines, toileting, communication, and safety. Use recumbent or supported positions, avoid unnecessary transfers and orthostatic testing, and cancel non-urgent appointments. Offer fluids and food in the least effortful form the patient can tolerate; assess swallowing, nausea, early satiety, abdominal symptoms, urine output, weight trajectory, and the need for dietetic or enteral support. Severe illness can make eating and drinking itself too demanding, and autonomic or gastrointestinal dysfunction can lead to serious malnutrition; very severe disease may require tube feeding. ^[115] Do not increase intake rapidly in a markedly malnourished patient without monitoring electrolytes and replacing abnormalities, because refeeding syndrome can cause arrhythmia, cardiac failure, delirium, seizures, or cardiac arrest, usually during the first 5 days after calories are introduced or increased. ^[115]

Reduce light, sound, touch, odour, conversation, screen exposure, and movement to the patient’s tolerated level. Ask permission before touching or repositioning, explain one step at a time, use written or text-based communication when tolerated, and allow long pauses. Severe and very severe ME/CFS may include marked hypersensitivity to light and sound, cognitive dysfunction, and orthostatic intolerance; a patient who can answer a brief question may still be unable to sustain conversation, process complex information, or tolerate routine examination. ^{[115] [76]} Designate one spokesperson, obtain collateral history from a trusted carer when consent permits, and avoid repeated questioning by multiple staff members.

Severe ME/CFS may leave only minimal activities, such as eating or personal hygiene, possible, with slow recovery after exertion and frequent need for mobility assistance. Very severe ME/CFS is characterised by being bedbound, dependence on others for basic care, and extreme sensitivity to light and sound. ^[76] In practice, assess function by domain: ability to leave bed, sit, stand, transfer, wash, toilet, eat, drink, speak, read, use a device, and tolerate light, sound, touch, or movement. Communication difficulty may reflect cognitive slowing, sensory overload, orthostatic deterioration, dysarthria, exhaustion, or inability to tolerate speech; never interpret reduced communication alone as refusal of care or lack of capacity.

Arrange urgent same-day assessment for syncope or recurrent presyncope, inability to maintain hydration, oliguria, suspected malnutrition or significant weight loss, inability to swallow, new pressure injury, unilateral limb swelling or pain, suspected thrombosis, fever or other evidence of infection, new hypoxaemia or respiratory compromise, chest pain, delirium, focal neurological deficit, rapidly progressive weakness, or haemodynamic instability. Assess suicidal thoughts, intent, access to means, neglect, coercion, abuse, unsafe caregiving, and inability to meet basic needs; escalate immediately when there is suicidal intent, impaired judgement, suspected abuse, or no safe plan for food, fluids, medicines, toileting, repositioning, or supervision. Severe ME/CFS can require long-term care or artificial nutrition, and, in extreme cases, can be fatal; these risks justify active medical and safeguarding review rather than diagnostic reassurance alone. ^[76]

Plan care around the patient’s activity envelope. Prefer a home visit, telemedicine, or collateral assessment when travel would require prolonged upright time, transfers, waiting, noise, or light exposure. If transport is unavoidable, use a recumbent option where available, pre-arrange access without waiting, minimise transfers, bring prescribed fluids and medicines, and have a written stop plan if symptoms escalate. Home-based assessment and staged, symptom-oriented procedures are being studied because hospital protocols can be intolerable for severe ME/CFS; even research procedures may need pausing or discontinuation when symptoms worsen. ^[76]

Before referral or admission, send a concise written care plan stating the diagnosis, usual and current function, PEM latency and recovery pattern, orthostatic limitations, communication method, sensory needs, medication list, allergies, nutrition and hydration risks, mobility and pressure-care requirements, and the interventions that have previously worsened symptoms. Ask the receiving team to provide a quiet, low-light environment; cluster essential care; avoid unnecessary observations, transfers, fasting, procedures, and repeated interviews; examine in the least upright position tolerated; and monitor for delayed deterioration after the immediate encounter. Use home nursing, primary care, dietetics, occupational therapy, physiotherapy experienced in ME/CFS, social care, and safeguarding services according to the problem rather than referring solely to a generic rehabilitation pathway. ^[76]

A crash that does not begin to stabilise after removal of the trigger, or that leaves the patient below the recent functional baseline, warrants reassessment for infection, dehydration, malnutrition, medication toxicity, sleep-related deterioration, cardiovascular or neurological disease, pressure injury, thrombosis, and safeguarding risk. Do not use the absence of a dramatic office finding to dismiss a delayed deterioration: the relevant outcome is the patient’s trajectory over the ensuing hours and days. ^[76]

Plan participation around the patient’s reliable usual activity envelope, not a best day, a target number of hours, or an exercise programme. A return to work or education should therefore be graded in demand, not in exercise: begin with the smallest sustainable combination of upright, cognitive, sensory, social, and travel demands; schedule recovery before symptoms escalate; and change one element at a time. Review the delayed response over the patient’s usual post-exertional window, and reduce to the last stable arrangement if symptoms worsen. A person may tolerate a brief task yet be unable to repeat it on consecutive days, so attendance alone does not establish sustainable capacity. Documentation of disability should describe the functional impact of post-exertional malaise and use objective or corroborative evidence where available. ^[122][134]

Use flexible scheduling rather than a simple full-time/part-time distinction. Options include later starts, shorter attendance periods, alternate days, fewer simultaneous subjects or duties, extended deadlines, fewer examinations, rest periods, and a slower academic or vocational progression. Remote participation can preserve teaching, supervision, or team contact when travel or the physical environment exceeds the activity envelope; offer asynchronous recordings, written instructions, chat, voice-to-text, and cameras that can remain off. Remote work is not automatically low demand: screen exposure, sustained attention, rapid communication, and domestic disruption may consume the same cognitive and sensory reserve as attendance on site. Qualitative studies of young people and school personnel describe fewer lessons, prolonged progression, planned rest, home assignments, maintained teacher contact, and online teaching as potentially useful adaptations, although these findings do not establish that any single arrangement will work for every patient. ^{[123][124][125]}

Reduce environmental load. Provide a quiet, dim, temperature-stable space; allow sunglasses, ear protection, noise-cancelling headphones, screen filters, reduced notification frequency, and written rather than spoken instructions. Permit seated or recumbent work, avoid unnecessary queues and prolonged standing, and arrange accessible toilets, nearby parking, a lift, or a rest room. Assistive technology such as dictation, text-to-speech, recorded lessons, electronic reminders, ergonomic peripherals, and simplified interfaces can reduce communication and processing demand. A wheelchair , rollator, shower chair, or other mobility aid may conserve upright capacity; its use is a functional adaptation, not evidence of unwillingness to walk. Occupational therapy can help translate the activity envelope into task-specific environmental changes. ^{[123][125][134]}

When attendance cannot be maintained within the envelope, reduce or suspend attendance without framing this as treatment failure. Maintain proportionate connection through a named contact, brief low-demand messages, home teaching, recorded material, or planned peer contact if tolerated. Reassess after stabilization rather than requiring the patient to “prove” readiness through attendance. For a young person, preserve educational membership and a route back without making return contingent on completing a fixed exercise or attendance quota. School personnel report that concrete plans, early adaptation, and continuity between teachers, families, health professionals, and school nurses are more workable than repeated debates about causation. ^[124][125]

Functional evidence and documentation

Write what the patient can sustain, what happens after the task, and what support makes it possible. “Unable to work” or “school refusal” is inadequate without the functional pathway. Record the task, duration, posture, cognitive and sensory demand, frequency, assistance required, symptom latency, worsened symptoms, recovery duration, and whether baseline returns. Distinguish a one-off performance from repeatable capacity across several representative days. Record cancelled or shortened activities, delayed recovery, transport dependence, communication limits, and the consequences of attempting more. A brief fluent consultation does not demonstrate capacity for a full workday, school day, commute, or sustained interaction.

Use collateral evidence with consent: attendance records, workload and deadline history, employer or teacher observations, occupational-therapy assessment, care logs, symptom/activity records, and prior functional baselines. Patient-reported limitation remains evidence when it is specific, internally consistent, longitudinally reproducible, and corroborated where possible; do not substitute assumptions about motivation, mood, personality, intelligence, parenting, or family conflict for functional assessment. A functional-capacity instrument may organize domains such as personal care, walking, upright activity, home tasks, communication, activity outside the home, light and sound tolerance, and concentration, but it does not replace clinical judgment. ^{[122][134][135]}

State the requested accommodation, its clinical rationale, duration, review date, and contingency plan. For disability benefits or sick leave, describe why the patient cannot sustain the essential demands of the role, why apparent capacity on a better day is not reliable capacity, and what assistance or environmental change would be required. Separate established findings from patient-reported symptoms, clinical inference, and uncertainty. Complete forms accurately and within the relevant jurisdiction’s rules; do not certify a legal entitlement that depends on an agency’s determination. Occupational therapists and other rehabilitation professionals may provide useful task-based evidence for disability claims. ^[122]

Access to care must be adapted to the same functional evidence. Offer telemedicine , telephone review, home visits, or a recumbent low-stimulation appointment when travel, waiting, transfers, noise, light, or prolonged upright posture are likely to provoke deterioration. Cluster essential assessments, use one coordinating clinician, share a concise written care plan, permit pauses, and avoid repeated questioning or unnecessary procedures. Arrange transport that allows reclining or rest, and provide an escort when transfers, communication, or safety require it. Patients with severe illness can be harmed by poorly adapted contact and may be excluded precisely because they cannot reach a clinic. ^{[49][131][133][137]}

Assess carers as patients with needs of their own. Ask who provides personal care, meals, medication support, transport, communication, supervision, and night-time care; quantify hours and identify what happens if that person becomes ill. Arrange respite, backup care, equipment, benefits advice, and practical training. Carer burden may include physical and emotional strain, financial and employment effects, and impact on the whole family; do not assume that relatives can indefinitely provide complex care without formal support. ^[127][131]

For children and adolescents, obtain the young person’s view in a format and duration they can tolerate, then involve parents or carers according to the young person’s wishes, age, and legal framework. Do not interpret limited speech, delayed replies, sensory withdrawal, or inability to attend a meeting as lack of understanding or refusal. Assess decision-making capacity for the specific decision at the relevant time, support communication, and document consent or lawful substitute decision-making. Agree who may share information with school, employer, social care, or benefits agencies, and share only what is necessary. A child-centred plan should preserve education, relationships, privacy, and development while recognizing that care-management capacity may fluctuate. ^[128][124]

Make advance plans while communication is possible: preferred contact method, acceptable lighting and sound, positioning, early warning signs of deterioration, essential medicines and fluids, emergency thresholds, people to contact, and preferred place of care. Include contingency arrangements for carer illness, loss of housing, transport failure, safeguarding concerns, and inability to eat, drink, toilet, communicate, or remain safe. Investigate suspected abuse, neglect, coercive control, financial exploitation, or unsafe caregiving through ordinary safeguarding pathways; severe disability must not be mistaken for family dysfunction, and family explanations must not be accepted uncritically when safety concerns arise. ^[49][131]

Ask what culturally appropriate support means to the patient and family rather than assuming that a standard home-care model is acceptable. Use interpreters rather than relatives when clinically or legally appropriate, accommodate religious practice, gender preferences, household structure, food practices, and community support, and check whether proposed carers, equipment, transport, or home visits are acceptable and affordable. Poverty, language barriers, ethnicity, rural residence, and absence from specialist care can alter access to documentation and services; they should never be treated as evidence against genuine functional impairment. ^{[130][132][133]}

The long-term course of ME/CFS is heterogeneous. Symptoms and function may fluctuate, with periods of partial improvement, relapse, or sustained disability rather than a single predictable trajectory. A patient’s current presentation therefore describes present burden, not a fixed forecast. In a small 16-year prospective follow-up of women, fatigue and selected cognitive, anxiety, and bowel symptoms were worse at reassessment, but the investigators emphasized that loss to follow-up, aging, and absence of a matched control group prevented causal or population-level prognostic conclusions.^[18] Use such findings to justify longitudinal review, not to predict an individual outcome.

Remission is possible, but the term requires care. In a U.S. National Health Interview Survey analysis, 20.7% of adults who had ever reported an ME/CFS diagnosis reported that they no longer had the condition; however, 40-50% of this group still reported symptoms and function similar to those of people with current ME/CFS, and only approximately 25% had substantially fewer symptoms and better function.^[4] Ask what “recovered” means: fewer symptoms, improved self-care, return to work or school, or durable restoration of the pre-illness activity envelope. Do not equate a good day, reduced fatigue, or a change in diagnostic labeling with remission. Judge improvement by sustainable function across repeated days and by the patient’s post-exertional response, not by a forced increase in activity.

Persistent disability may remain substantial even when routine examination findings are normal. In a nationwide New Zealand study of people with ME/CFS receiving a health- or disability-related benefit, only 18.3% were currently employed compared with 83.8% of a general-population comparison group; this selected cohort cannot represent all people with ME/CFS, but it illustrates the functional and socioeconomic burden in those requiring disability support.^[35] Function may be poorer when orthostatic symptoms, cognitive impairment, sleep instability, pain, malnutrition, comorbid disease, or repeated PEM coexist. In a tertiary pediatric post-COVID registry, severe disease was associated with acute orthostatic intolerance, trouble concentrating, a greater number of acute symptoms, and female sex, while these associations did not establish deterministic predictors for ME/CFS in other populations.^[11] Conversely, improvement in one domain does not guarantee recovery in another: a patient may walk farther yet remain unable to tolerate sustained upright time, conversation, screen use, or school attendance without delayed worsening.

Follow-up should repeatedly compare the patient’s current sustainable activity envelope with the previous stable baseline. Ask about the trigger, latency, symptom change, and recovery time for the most recent PEM episode; document whether the patient returns to baseline or remains below it. Review sleep over several nights rather than relying on a single night’s impression, because free-living ME/CFS cohorts show poor sleep efficiency and substantial night-to-night variability.^[8] Reassess orthostatic symptoms, hydration, nutrition and weight, swallowing, medication effects, comorbidities, mood, suicidal thinking, neglect or abuse, carer capacity, work or education demands, and the accommodations needed to make care accessible. Investigate new focal, abrupt, severe, progressive, or qualitatively different symptoms independently; do not attribute them automatically to ME/CFS.

Use the format and interval that the patient’s severity permits. Mild or moderate illness may allow planned clinic or video review; severe or very severe illness may require telephone, remote, home-based, or recumbent review, collateral history, low-stimulation communication, and clustered essential care. Flexible digital, hybrid, and modular support is particularly relevant when physical or cognitive limitations make conventional appointments burdensome, while qualitative evidence also emphasizes continuity and structured follow-up.^[44] Increase review frequency after a relapse, infection, procedure, medication change, nutritional decline, safeguarding concern, or emerging red flag. A stable patient may need less frequent planned review, but retain a written route for earlier contact.

Do not use follow-up to enforce a predetermined exercise target or quota. If function improves, consolidate the improvement and test sustainability before considering a small, patient-led change; if delayed worsening follows, return to the last stable arrangement. The clinically meaningful endpoint is a larger and more reliable activity envelope with fewer or shorter exacerbations, not completion of a rehabilitation schedule.

Research priorities should match the clinical problem’s heterogeneity. Biomarker studies need rigorously defined participants, appropriate disease and healthy comparison groups, standardized sample collection, and replication; otherwise biological signals may reflect case-definition differences, illness duration, medication, or selection bias.^[42] Systematic review evidence describes heterogeneous biomarker methods and calls for larger longitudinal cohorts to validate candidate markers.^[86] The goal is a biomarker that improves diagnosis, phenotyping, prognosis, or treatment selection, not a laboratory label that replaces clinical assessment before validation.

Mechanistic research should connect immune, autonomic, vascular, sensory, metabolic, sleep, and cognitive findings to delayed functional deterioration and PEM. Longitudinal designs should separate state markers from stable susceptibility and should measure recovery trajectories, not only single time-point abnormalities. Multimodal subgrouping is a research strategy, not standard clinical care: proposed studies combine autonomic, neuropsychological, inflammatory, neuroimaging, microbiome, neuroendocrine, and ecological measures to identify subgroups and predictors of response.^[120] Such approaches require external validation and must not be used to assign an unvalidated biological subtype in routine practice.

Pediatric disease needs dedicated prospective cohorts that account for development, school participation, family context, consent and assent, and changing activity demands. Repeated handgrip testing in young people was feasible and reflected physical impairment, but it had limited ability to distinguish ME/CFS from other fatiguing conditions, so it is an outcome or phenotyping measure rather than a standalone diagnostic biomarker.^[14] Postinfectious cohorts should recruit near the inciting illness when possible, retain participants across recovery and relapse, and distinguish post-COVID condition from ME/CFS while studying their overlap; a small two-timepoint study found overlapping autonomic, sensory, cognitive, and symptom profiles but cannot establish a universal shared trajectory.^[26]

Outcome research should prioritize sustainable function, PEM frequency and recovery, cognitive and orthostatic capacity, participation, quality of life, symptom variability, and harms, with measures validated across severity levels and modes of administration. Include people who are housebound or bedbound through remote, home-based, low-burden methods; participatory design can reduce selection bias and improve representativeness because severe disability otherwise limits research access.^[141] Treatment trials must report delayed adverse effects, relapse, withdrawal, and function over time, not only immediate fatigue scores. Symptom-directed care and individualized energy management remain clinical care; unproven antivirals, immunomodulators, metabolic agents, fixed-increment exercise programs, and other experimental interventions belong in appropriately governed research, not routine treatment. The absence of a definitive treatment remains a reason to improve trials, not a reason to expose patients to uncontrolled therapeutic experimentation.^[18]